

EFFECT OF KOREAN RED GINSENG ON EICOSANOID BIOSYNTHESIS IN PLATELETS AND VASCULAR SMOOTH MUSCLE CELLS

Y. Tamura, A. Hirai, T. Terano, K. Tahara, J. Saitoh, S. Kondo,
K. Samukawa* & S. Yoshida

The 2nd Department of Internal Medicine, Chiba University School of Medicine Chiba 260, Japan
** Japan Korean Red Ginseng Co., Ltd. Kobe, Japan*

INTRODUCTION

Platelet hyperfunction such as enhanced platelet aggregability associated with overproduction of TXA₂, a potent anti-platelet aggregatory and vasoconstrictive substance, has been frequently encountered in patients with cerebral and cardiovascular thrombotic diseases. Prostacycline (PGI₂), a potent anti-platelet aggregatory and vasodilatory substance produced in vascular walls, also has been reported to be less synthesized in patients with atherosclerotic changes than normal subjects.

We previously described that oral administration of ginsenoside Rg₁ (G-Rg₁) or G-Rg₃, main components of Korean Red Ginsengs (KRGs) has a potent anti-platelet aggregatory action. Thus KRGs may have anti-thrombotic effect and thereby may be useful for prevention and treatment of atherosclerotic and thrombotic disorders.

Accordingly the present investigations were performed to study the effect of KRGs on eicosanoid biosynthesis in platelet and vascular walls in order to elucidate further in detail the anti-thrombotic action of KRGs.

STUDY OF GINSENG SAPONIN ON EICOSANOID BIOSYNTHESIS AND AGGREGABILITY OF PLATELETS

We previously reported that in vitro study among various ginseng saponins, only G-Rg₁ and G-Rg₃ had a potent suppressive effect on platelet aggregation stimulated by various aggregants such as collagen, ADP, epinephrine and arachidonic acid (AA). Also G-Rg₁ inhibited 9, 11-epithio-11, 12-methano-TXA₂ (stable TXA₂: STXA₂)-induced platelet aggregation, while the specific binding of [³H]SQ29548 (specific TXA₂ receptor antagonist) to human platelet was not affected. Agents which increases cAMP and cGMP levels in platelets have been described to inhibit platelet aggregation. So we investigated the effect of G-Rg₁ on the basal levels of these two cyclic nucleotides in washed platelets. G-Rg₁ had no effect on the basal levels of cAMP and cGMP. Therefore this possibility seems to be less likely. Interesting finding is that when measured by Quin 2, an increase of cytosolic Ca⁺⁺ in platelets stimulated by STXA₂

was dose dependently decreased by in vitro addition of G-Rg₁ with resultant decrease of platelet aggregation.

2.7 g/day of KRGs was orally administered to 10 patients with cerebro- and cardiovascular thrombotic diseases for 4 weeks. Platelet aggregability induced by collagen or V46619 (one of the STXA₂) was significantly suppressed with a concomitant decrease of TXA₂ production. On the basis of these results obtained by the in vitro and in vivo experiments, it is our thought that G-Rg₁ or G-Rg₃ may exert its anti-platelet aggregatory action by decreasing TXA₂ formation in platelets most likely by inhibiting Ca⁺⁺ influx.

Urinary excretion of 11-dehydro-thromboxane B₂ (11-dehydro TXB₂), one of the major metabolites of TXA₂ and 2, 3-dinor-6-Keto-PGF_{1α}, one of the major metabolites of PGI₂ were determined in 20 patients with various cardiovascular thrombotic disorders after 4 weeks of oral ingestion of 2.7 g/day of KRGs.

Collagen or ADP-induced platelet aggregation was significantly decreased. On the other hand, urinary excretion of 2, 3-dinor-6-Keto-PGF_{1α} was significantly increased, while that of 11-dehydro-TXB₂ was unchanged. Therefore the ratio of 2, 3-dinor-6-Keto-PGF_{1α} to 11-dehydro-TXB₂ (PGI₂-M/TXA₂-M) was significantly increased after 4 week administration of KRGs.

STUDY OF PGI₂ PRODUCTION IN VASCULAR SMOOTH MUSCLE CELLS

In cultured smooth muscle cells obtained by rat thoracic aorta, conversion of ¹⁴C-AA to ¹⁴C-6-Keto-PGF_{1α} was determined after co-incubation with various ginsenosides. Interestingly only by addition of G-Rc, enhanced conversion of ¹⁴C-AA to ¹⁴C-6-Keto-PGF_{1α} was noted. On the other hand, conversion of ¹⁴C-PGH₂ to ¹⁴C-6-Keto-PGF_{1α} was unchanged. Northern blot analysis of total RNA prepared from vascular smooth muscle cells showed that in vitro addition of G-Rc increased mRNA level of cyclooxygenase in smooth muscle cells. These results indicate that the enhanced PGI₂ formation by G-Rc could be partly ascribed to an increased cyclooxygenase activity and that G-Rc stimulated gene expression of cyclooxygenase in G-Rc treated vascular smooth muscle cells.

SUMMARY

From in vivo and in vitro experiments using Korean Red Ginseng and its main components, ginsenoside saponins, it was found that ginsenoside may exerts its anti - thrombotic action by decreasing TXA₂ formation in platelets and increasing PGI₂ formation in vascular walls. This may certainly contribute to prevention and development of atherosclerosis and thrombosis by administration of Korean Red Ginsengs.